Clinical trials

The purpose of this randomized controlled study is to explore whether lavender sandalwood aromatherapy can support comfort, mood, pain relief, and overall satisfaction for participants recovering from a scheduled cesarean section without complications. The main questions this study aims to answer are: * How does lavender sandalwood aromatherapy affect participants' mood during postpartum recovery after a cesarean section? * Does lavender sandalwood aromatherapy help reduce pain during recovery? * Does lavender sandalwood aromatherapy improve participants' overall satisfaction with their recovery experience? Researchers will compare participants who receive lavender-sandalwood aromatherapy with those who do not to determine whether it improves mood, reduces pain, and enhances patient satisfaction. Participants will be asked to: * Wear aromatherapy tabs on their gown for 24 hours. * Have the aromatherapy tabs applied 24 hours after the cesarean section and removed 48 hours after the cesarean section. * Complete surveys at 24 hours and 48 hours after the cesarean section. This will apply to both the control and intervention groups.

In this pilot safety study, the investigators will give a second dose of Intravenous Tenecteplase (IV TNK) to patients receiving the initial TNK dose within 3 hrs of last known normal (LKN), have a baseline National Institutes of Health Stroke Scale (NIHSS) \> 6, and who do not clinically improve within 45 minutes of the first dose, or who improve but then deteriorate, and can still be treated within 4.5 hours from LKN. Patients will require a second computed tomography (CT) scan to rule out any bleeding, and meet the usual inclusion and exclusion criteria for TNK treatment, before the second dose which must be given within 4.5 hrs of LKN. Both TNK doses will be 0.25 mg/kg. The initial TNK dose may be given on the Mobile Stroke Unit (MSU) or Emergency Department (ED), and the second dose in the ED. Informed consent will be obtained before the second dose is given. The primary outcome will be symptomatic intracranial hemorrhage (sICH) (SITS-MOST criteria) or serious systemic bleeding within 36 hours. Secondary outcomes will be any intracranial hemorrhage, any bleeding, discharge NIHSS and modified Rankin Score (mRS), and mRS at 90 days (sliding dichotomy). 20 patients will be enrolled. Enrollment will be stopped if more than 3 sICH occur (\> 80% confidence that sICH rate is \> 5%. If successful, this study will be followed by a larger phase 2b controlled safety confirmation and pilot efficacy study,